Yahoo Finance

After Intra-Cellular Therapies (ITCI) announced that it has entered into a settlement agreement with Sandoz (SDZNY) resolving patent litigation related to Intra-Cellular Therapies’ product Caplyta, RBC Capital notes this makes Sandoz the first of the seven ANDA filers to reach a deal. More favorable-than-expected terms for first generic lumateperone settlement bode well for Intra-Cellular’s ability to maintain Caplyta revenue durability, says the firm, which “would be buyers into strength.” RBC maintains an Outperform and $108 price target on the shares.

Stay Ahead of the Market:

• Discover outperforming stocks and invest smarter with Top Smart Score Stocks

• Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on ITCI:

• Intra-Cellular settles Caplyta patent litigation with Sandoz

• Intra-Cellular price target lowered to $108 from $112 at RBC Capital

• Intra-Cellular presents data from CAPLYTA adjunctive MDD Phase 3 program

• Intra-Cellular recently submitted a sNDA to the U.S. FDA for CAPLYTA for MDD